Login to Your Account



Pfizer Suspends Massive Phase III OA Program

By Trista Morrison


Friday, June 25, 2010
As Pfizer Inc. suspended development of a massive clinical program for osteoarthritis pain, the question on every biotech's lips likely was whether the antibody, tanezumab, or the target, nerve growth factor (NGF), was at fault. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription